🇺🇸

US SEC Filing Intelligence

· daily

US Corporate Distress Financial Stress SEC Filings — May 07, 2026

Across 50 filings in the USA Corporate Distress & Bankruptcy stream dated May 7, 2026, a dominant theme is aggressive capital raising via convertible notes, senior debt, equity offerings, and PIPEs (e.g., ProPetro $600M upsized, Avalo $405M net proceeds), signaling liquidity bolstering amid potential distress but with positive sentiment in 60% of cases. Period-over-period trends show mixed results: revenue growth in 8/15 reporting companies (avg +35% YoY, e.g., MP Materials +49%, Resolute management fees +1073%), but persistent net losses/cash burn (e.g., MP -$8M, Kodiak -$35M FCF) and margin compression (Fox Factory -150 bps EBITDA margin). M&A activity highlights value extraction with take-private premiums (Cross Country 31%, Catalyst 21%), while distress signals cluster in small caps: 4 Nasdaq non-compliance notices (Polar Power equity $144K vs $2.5M req, Smart Powerr delisting risk May 12), covenant waivers/forbearances (Mercer €370M facility, Wellgistics $1.77M loan, Buzzfeed $5M repayment default). Capital allocation leans toward buybacks/debt paydown (Life Time $63M repurchase, Ocugen $33M loan repayment) over dividends. Portfolio-level, healthcare leads positive catalysts (3 acquisitions/offerings), energy/mining mixed operational ramps but funding dependency; implications include short-term stabilization but heightened bankruptcy risk for non-compliant microcaps.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — May 07, 2026

Across 40 filings in the USA Executive & Director Changes stream (May 7, 2026), a dominant theme is proactive leadership transitions, with 12 CFO/controller-related changes (e.g., ITT interim CFO, Pagaya CFO succession, Shake Shack new CFO) and 8 new executive/director appointments signaling strategic refreshes amid growth phases. Period-over-period trends show mixed financial health: 7/12 companies with financials reported YoY revenue growth averaging +8% (e.g., Pagaya +10%, Nature's Sunshine +9%, Perdoceo +4.1%), but impairments/losses in energy/biotech (Ring $220M net loss, Arcturus -93% revenue) and margin contractions (Pagaya -19bps FRLPC). AGM outcomes were overwhelmingly positive (15/15 passed all proposals, avg >90% support), affirming governance stability. Capital allocation leans shareholder-friendly with dividends (Perdoceo $0.15/share), buybacks (Post $600M new auth), and ESPPs (Rogers, Telos). Portfolio-level, bullish signals from guidance raises (Pagaya FY GAAP net $110-160M) and insider-aligned comp (SenesTech CEO 5% equity) outweigh neutral departures, but vague filings (Power Integrations, STERIS) flag opacity risks. Implications: Opportunities in leadership-upgraded growth names (AudioEye, Proto Labs), caution on interim-heavy transitions.

40 high priority 40 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 07, 2026

Across 39 US SEC filings focused on board room changes from May 7, 2026, a dominant theme is elevated C-suite turnover, particularly CFO and executive roles, with 12 instances of departures, appointments, or interim placements (e.g., ITT, Pagaya, Shake Shack, multiple New Mountain entities), signaling potential strategic shifts amid mixed financial performances. Annual general meetings (AGMs) in 12 companies showed overwhelming approvals for directors, auditors, and incentive plans (e.g., Rogers, Telos, Pediatrix), reflecting strong shareholder confidence and board stability. Period-over-period trends reveal robust revenue growth in 7 firms averaging +11% YoY (Pagaya +10%, Nature's Sunshine +9%, AudioEye quadrupling since 2019), but margin pressures in others (Pagaya FRLPC -19 bps YoY, Ring Energy impairments) and biotech trial mixed results (enGene 54% CR but 25% at 12 months). Positive capital allocation includes Post Holdings' $600M buyback authorization and multiple ESPP approvals; forward guidance raised in Pagaya (FY2026 Adj EBITDA $420-460M) and affirmed in Post ($1.55-1.58B). Portfolio-level patterns highlight hospitality/data (Target Hospitality), biotech volatility (enGene, Arcturus), and energy mixed ops (Ring, Peabody), with actionable implications for monitoring leadership transitions as catalysts for outperformance or distress.

39 high priority 39 total filings
· daily

US Merger & Acquisition SEC Filings — May 07, 2026

A surge in SPAC IPO activity dominates the 19 filings, with 7 blank-check companies (Irenic, ARC Group, Mountain Crest, RRE Ventures, Forefront Tech, GP-Act III) completing IPOs raising aggregate ~$883M at $10/unit, signaling robust appetite for de-SPAC opportunities amid extended deadlines to Nov/July 2026. Energy sector consolidation peaks with Devon Energy completing undisclosed asset acq/disposition and Coterra merger (0.70 Devon shares/share), leading to delisting and cessation of reporting, while VSE Corp's $2.025B PAG aviation acq boosts pro forma 2025 revenue ~50% and targets >20% EBITDA margins. Media (Gray $171M stations) and construction (Suncrete Nelson Bros acq) show accretive bolt-ons expanding footprints, contrasted by Carnival's high-risk restructuring (delisting, control change) and neutral filings lacking details (Sculptor, Shuttle). No broad YoY/QoQ declines noted, but increased debt (VSE $900M Term Loan B, Acura $10.3M principal) and dilutions (Blue Acq 12% incentive pool) emerge; positive sentiments in 9/19 filings drive M&A momentum. Portfolio trend: Acquisitions accretive across sectors (avg implied revenue lift 30-50%), SPAC trust funding intact for catalysts.

19 high priority 19 total filings
· daily

Biotech Small-Cap Approvals — May 06, 2026

The May 6, 2026 period delivered 6 Other approvals in the biotech small-cap stream (0 NME, 0 biosimilar, 0 label expansion), generating 3 bullish and 3 neutral signals with no bearish outcomes. While no dominant therapeutic area theme is evident, oncology stands out with three approvals including label expansions for TRABECTEDIN (APOTEX INC) and RUXOLITINIB PHOSPHATE (INCYTE CORPORATION) alongside the highest-conviction VEPDEGESTRANT NME for ARVINAS OPERATIONS INC, signaling first-in-class potential with 5-year NCE exclusivity and strong unmet need. Biosimilar approvals for SITAGLIPTIN (BIOCON PHARMA LTD), TORSEMIDE (MICRO LABS), and MIRABEGRON (DEVA HOLDING AS) introduce neutral entrant upside but bearish competitive erosion risks for originators like Merck (Januvia) and Astellas (Myrbetriq). Key risk/watch item: post-approval launch execution for ARVINAS OPERATIONS INC's VEPDEGESTRANT amid competitive oncology dynamics.

6 total filings
· daily

Orphan Drug Approvals — May 06, 2026

During May 6-6, 2026, the FDA issued 1 orphan drug approval, comprising 0 NMEs, 0 biosimilars, 0 label expansions, and 1 Other, generating 1 bullish signal. INCYTE CORPORATION's label expansion for RUXOLITINIB PHOSPHATE (JAKAFI XR) marks the period's sole event, signaling incremental upside in the orphan space without a dominant therapeutic area theme due to the single approval. This represents the highest-conviction signal, offering INCYTE CORPORATION potential revenue diversification from an established asset amid NOT_DISCLOSED commercial details. No bearish or neutral signals emerged. Key risk/watch item: limited visibility into peak sales, exclusivity, pricing, and market position requires monitoring post-approval performance.

1 total filings
· daily

New Drug Approvals (Original) — May 06, 2026

This week's 6 FDA 'Other' approvals (0 NME, 0 biosimilar, 0 label expansion) feature a mix of label expansions, biosimilars, and one NME, with 3 bullish and 3 neutral signals but no dominant therapeutic area clustering. Highest-conviction signal is ARVINAS OPERATIONS INC's NME approval for VEPDEGESTRANT (VEPPANU), a strong pipeline execution indicator with 8/10 strength and materiality, implying 5-year NCE exclusivity and significant commercial upside. Bullish label expansions for TRABECTEDIN (APOTEX INC) and RUXOLITINIB PHOSPHATE (JAKAFI XR, INCYTE CORPORATION) enhance sponsor franchises, while neutral biosimilar approvals for SITAGLIPTIN (BIOCON PHARMA LTD), TORSEMIDE (MICRO LABS), and MIRABEGRON (DEVA HOLDING AS) pose modest competitive entry without originator erosion quantified. Key risk/watch item: competitive dynamics from biosimilar entrants potentially pressuring originators over 2-3 years.

6 total filings
· daily

VA Healthcare & Services Contracts — May 06, 2026

These two VA Healthcare & Services contracts aggregate $328,828,352 in total obligations, with a 0/2 defense-related split, entirely within civilian VA exposure. The dominant agency theme is Department of Veterans Affairs support services, led by Vendor Resource Management, Inc.'s $200,641,730 real estate management award (materiality 6/10) and Favor TechConsulting, LLC's $128,186,621 IT development delivery order (materiality 5/10). Highest-conviction signal is neutral (avg 4/10 strength) across both full-and-open competition awards to private firms. A key risk is low outlay progress—$38,359,535 (19%) for Vendor Resource and $16,478,924 (13%) for Favor TechConsulting—signaling potential execution delays. Watch option exercises toward $374M and $185M ceilings ahead of 2025-09-30 and 2026-09-29 ends.

2 total filings
· daily

New Federal Contractors — May 06, 2026

These four new federal civilian contracts total $737,191,282 in obligations, with zero defense-related awards across NASA, VA (two contracts), and GSA. Dominant themes include long-term civilian infrastructure modernization (GSA construction) and VA real estate/IT services, reflecting steady non-DOD spending priorities. Highest-conviction signal is bullish on Hensel Phelps Construction Co.'s $188,297,215 GSA contract, with 76% ($143M) outlayed and performance through mid-2026. Neutral signals dominate for Peraton Inc. ($220M NASA), Vendor Resource Management Inc. ($200M VA), and Favor Techconsulting LLC ($128M VA), due to partial execution. Key risk is low outlay progress on VA contracts (e.g., $38M of $200M for Vendor Resource Management), vulnerable to budget scrutiny amid CR uncertainty.

4 total filings
· daily

Significant Contract Modifications ($10M+) — May 06, 2026

These four significant contract modifications total $737,191,282 in obligations, all civilian with zero defense-related awards across NASA, VA (two contracts), and GSA. Dominant themes include VA real estate management and IT services alongside NASA R&D operations and GSA construction, reflecting steady civilian infrastructure and support spending. Highest-conviction signal is bullish for Hensel Phelps Construction Co.'s $188,297,215 GSA contract, with 76% ($143M) outlayed and performance to 2026. Neutral signals dominate for Peraton Inc. ($220M NASA), Vendor Resource Management Inc. ($200M VA), and Favor Techconsulting LLC ($128M VA) due to partial execution. Key risk is low outlay progress in VA contracts (e.g., only 19% for Vendor Resource, 13% for Favor), signaling potential execution hurdles amid fixed-price structures.

4 total filings
· daily

Contract Deobligations Alert — May 06, 2026

These four civilian contract deobligations total $737,191,282 in obligations with 0/4 defense-related, highlighting steady execution in NASA, VA, and GSA programs but no DOD exposure. Dominant themes include VA real estate/IT services ($328.8M across two awards) and infrastructure construction via GSA. Highest-conviction bullish signal is Hensel Phelps Construction Co.'s $188M GSA contract with 76% ($143M) outlayed and low pricing risk through 2026. Key watch item: low outlay progress in VA contracts (e.g., Vendor Resource Management's $38M of $200M and Favor TechConsulting's $16M of $128M), signaling potential non-exercise of options or execution delays.

4 total filings
· daily

Contract Option Exercises — May 06, 2026

Four civilian agency contract option exercises totaling $737,191,282 in obligations highlight steady federal spending on long-term services and infrastructure, with 0/4 defense-related awards spanning NASA, VA (two contracts), and GSA. VA dominates with $328,828,351 combined across Vendor Resource Management ($200M) and Favor TechConsulting ($128M) for real estate and IT services. Highest-conviction bullish signal is Hensel Phelps Construction Co.'s $188,297,215 GSA construction project at 76% outlay ($143M disbursed), signaling reliable revenue through 2026. Peraton Inc.'s $220M NASA balloon facility operations adds neutral long-term NASA exposure at 41% outlay. Key risk: Low outlay execution in VA contracts (Vendor Resource at 19%/$38M, Favor TechConsulting at 13%/$16M), vulnerable to budget scrutiny or non-exercise of options.

4 total filings
· daily

Federal Professional Services Contracts — May 06, 2026

This digest covers a single $220,065,714 obligation contract to Peraton Inc. from NASA Goddard Space Flight Center, comprising 100% civilian awards with 0/1 defense-related. The dominant theme is steady NASA funding for GOCO R&D facility operations (PSC M1HA) via a 10-year cost-plus-fixed-fee structure under full and open competition. Highest-conviction signal is neutral (5/10 strength, 6/10 materiality), reflecting $89.9M outlayed (41% of obligation) and $21.5M estimated annual revenue through 2025. Partial execution includes $71.6M in 261 subawards, indicating subcontractor reliance. Key risk: contract expiration on 2025-04-30 with $130M remaining obligation, requiring monitoring for follow-on awards.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — May 06, 2026

The single contract analyzed totals $128,186,621 in obligations, entirely civilian with 0/1 defense-related, focused on Department of Veterans Affairs (VA) IT and telecom business application development support services. FAVOR TECHCONSULTING, LLC received this firm fixed-price delivery order via full and open competition, with a neutral signal (strength 4/10) due to low outlay of only $16,478,924 against the obligation and unexercised options up to $185,860,363 ceiling. The highest-conviction signal is neutral sector exposure in VA healthcare workflow IT tools under NAICS 541512. Key risk is high pricing risk on the fixed-price structure amid low execution to date; watch outlay progress and option exercises through the 2026-09-29 end date.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — May 06, 2026

These four civilian mega contracts total $737,191,282 in obligations, with 0/4 defense-related, spanning NASA, VA, and GSA agencies. VA dominates with two awards totaling $328,828,351 to Vendor Resource Management, Inc. ($200M) and Favor TechConsulting, LLC ($128M) for real estate management and IT services. Highest-conviction signal is bullish on Hensel Phelps Construction Co.'s $188M GSA construction contract, 76% outlayed with steady progress toward 2026 completion. Peraton Inc.'s $220M NASA balloon facility operations provide steady long-term revenue ending 2025. Key watch item: low outlays on VA contracts (under 20% for both), signaling execution risks amid fixed-price structures.

4 total filings
· daily

High-Value Federal Grants ($5M+) — May 06, 2026

These four high-value civilian federal grants, totaling $737,191,282 in obligations with zero defense-related awards, highlight steady execution in infrastructure and services sectors led by the Department of Veterans Affairs (VA) at ~$329M across two contracts and General Services Administration (GSA) infrastructure via Hensel Phelps. The highest-conviction signal is bullish on Hensel Phelps Construction Co.'s $188,297,215 GSA contract, with 76% ($143M) already outlayed on a cost-plus incentive fee structure for Calexico West Land Port modernization, signaling reliable revenue through 2026. Neutral signals dominate Peraton Inc. ($220M NASA balloon facility ops), Vendor Resource Management ($200M VA real estate), and Favor Techconsulting ($128M VA IT), where low outlays (e.g., 19% on Vendor, 13% on Favor) temper near-term revenue recognition. A key risk is execution delays on under-outlayed VA contracts amid fixed-price structures, warranting watches on option exercises and 2025-2026 end dates.

4 total filings
· daily

General Federal Contracts — May 06, 2026

These four civilian contracts total $737,191,282 in obligations with zero defense exposure, highlighting steady federal spending in NASA R&D operations, VA real estate/IT services, and GSA construction. Dominant themes include VA awards totaling $328,828,351 across Vendor Resource Management ($200M) and Favor TechConsulting ($128M), alongside major infrastructure at GSA ($188M to Hensel Phelps). The highest-conviction signal is bullish for Hensel Phelps Construction Co., with $143M (76%) already outlayed on its $188M GSA contract nearing completion in 2026. Key risk is execution delays from low outlays in VA contracts (Vendor Resource at 19%, Favor TechConsulting at 13%), warranting monitoring of option exercises and performance milestones.

4 total filings
· daily

All NASA Contracts — May 06, 2026

NASA accounts for the full $220,065,714 obligation across this single civilian contract stream (0 defense-related), centered on Peraton Inc.'s long-term operations and management of the NASA Balloon Facility. Awarded via full and open competition in 2014, the cost-plus-fixed-fee contract provides Peraton with an estimated $21.5M in steady annual revenue through April 2025, with $89.9M (41%) already outlayed and $71.6M via 261 subawards. The highest-conviction neutral signal (5/10 strength, 6/10 materiality) reflects low pricing risk but partial execution and subcontractor reliance. A key watch item is progress on the remaining $130M obligation ahead of the 2025-04-30 end date and potential follow-on awards.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 06, 2026

Across 39 filings in the S&P 500 Technology stream, institutional 13F-HR reports (e.g., Munro, Amica, Palladiem) reveal persistent heavy concentration in core tech names like NVIDIA (top holding in 4/10 13Fs, $288M-$61M positions), Apple, Microsoft, Amazon, and Meta, signaling sustained conviction amid AI/hardware boom. Operational tech firms showed divergent Q1 2026 trends: AMD revenue +38% YoY to $10.3B, EPS +91% to $0.84; Arista +35% to $2.7B, op income +35% to $1.16B; contrasting Ribbon's -10% revenue decline to $163M and widening net loss. Non-tech inclusions highlight cross-sector capital shifts, with positive turnarounds in shipping (Genco +61% rev) but weakness in BDCs (Palmer Square NAV -11% QoQ). Capital allocation mixed: Arista paused buybacks after $787M prior year, while Genco hiked dividend 133% YoY to $0.35/share; forward guidance stable/reaffirmed in Acadia/Immunocore. Portfolio-level: 7/12 10-Qs showed revenue growth averaging +22% YoY, but margin pressures in 4/12 (avg -50bps compression). Key implication: Tech growth intact but watch cash burn/expenses in smaller caps; institutional flows favor AI leaders.

16 high priority 23 medium 39 total filings